Maple syrup urine disease (MSUD) is a disorder of branched-chain amino acids (BCAA). The defect in the branched-chain ␣-keto acid dehydrogenase complex activity leads to an accumulation of these compounds and their corresponding ␣-keto-acids and ␣-hydroxy-acids. Studies have shown that oxidative stress may be involved in neuropathology of MSUD. l-carnitine (l-car), which has demonstrated an important role as antioxidant by reducing and scavenging free radicals formation and by enhancing the activity of antioxidant enzymes, have been used in the treatment of some metabolic rare disorders. This study evaluated the oxidative stress parameters, di-tyrosine, isoprostanes and antioxidant capacity, in urine of MSUD patients under protein-restricted diet supplemented or not with l-car capsules at a dose of 50 mg kg −1 day −1 . It was also determined urinary ␣-keto isocaproic acid levels as well as blood free l-car concentrations in blood. It was found a deficiency of carnitine in patients before the l-car supplementation. Significant increases of di-tyrosine and isoprostanes, as well as reduced antioxidant capacity, were observed before the treatment with l-car. The l-car supplementation induced beneficial effects on these parameters reducing the di-tyrosine and isoprostanes levels and increasing the antioxidant capacity. It was also showed a significant increase in urinary of ␣-ketoisocaproic acid after 2 months of l-car treatment, compared to control group. In conclusion, our results suggest that l-car may have beneficial effects in the treatment of MSUD by preventing oxidative damage to the cells and that urine can be used to monitorize oxidative damage in patients affected by this disease.
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Introduction
Maple syrup urine disease (MSUD) is a metabolic disease caused by a severe deficiency of the branched-chain ␣-keto acid dehydroAbbreviations: ABTS, 2,2 -azino-di-3-ethylbenzthiazoline sulfonate; BCAA, branched-chain amino acids; BCKAD, branched-chain ␣-keto acid dehydrogenase; Di-tyr, di-tyrosine; ELISA, enzyme-linked immunoassay; GC/MS, gas chromatography-mass spectrometry; HPLC, high-pressure liquid chromatography; HRP, horseradish peroxidase; KIC, ␣-ketoisocaproic acid; Leu, leucine; l-car, l-carnitine; LC/MS/MS, liquid chromatography electrospray tandem mass spectrometry; MRM, multiple reaction monitoring; MSUD, Maple syrup urine disease.
* genase complex (BCKAD) activity. The blockage of this pathway leads to the accumulation in tissues and body fluids of branchedchain amino acids (BCAA) leucine (Leu), isoleucine and valine and their respective ␣-keto-acids, ␣-ketoisocaproic acid (KIC), ␣-keto-␤-methylvaleric acid and ␣-ketoisovaleric acid, as well as the corresponding ␣-hydroxy acids, the ␣-hydroxyisocaproate, ␣-hydroxy-␤-methylvalerate and the ␣-hydroxyisovalerate (Treacy et al., 1992; Chuang and Shih, 2001; Harris et al., 2004) . Based on the clinical presentation and biochemical responses to thiamine administration, MSUD patients can be divided into five phenotypes: classic, intermediate, intermittent, thiamineresponsive and dihydrolipoyl dehydrogenase (E3) deficient (Chuang and Shih, 2001 ). The main signs and symptoms presented by MSUD patients include psychomotor delay and mental retardation, coma, convulsions, poor feeding, apnea, ataxia, ketoacidosis, hypoglycemia, as well as generalized edema and
